Intellectual Property - Essay Example

It is able to prevent and treat diabetic complications. It contains fagomine and 1-deoxynojirimycin whereby the ratio of their weights is 0.5, which is approximately 5:1. The preferred weight ratio is 2 which implies about 5:1 ratio of the weight of 1-deoxynojirimycin to that of fagomine. Firstly, this invention focuses its research on the role of ensuring reduction in blood glucose of the composition of fagomine and 1-deoxynojirimycin through the mixing of different ratios. The expected result is that the two compounds would have very good synergistic hypoglycemic effect within a set proportion range.

The mixing ratio selected is that with a better synergistic hypoglycemic effect. In addition, it also researches the effect of the composition when combined with other hypoglycemic compounds. In the event of reducing hypoglycemic rats’ blood glucose after intragastric sucrose administration, joint application of other hypoglycemic substances and fagomine and 1-deoxynojirimycin are able to more effectively reduce blood glucose than any other hypoglycemic compounds or any single or combined applications.

This composition can be made in to various formulations such as capsules, tablets, granules, dripping pills, powder, and oral liquid. Conventional methods and conventional excipients can be adopted as the preparation methods. From the research results, it is clear that the present applications has well spelt-out mechanism and significance usefulness which can be employed in preventing and treating diabetes and any complications accompanied with it. This issued patent operates in the Biomedical and technology field and address the concerns of the diabetes menace which over the years has claimed more lives just as much as cancer and HIV/AIDS.

The novel thing about this invention is how it utilizes the capability of compositions to synergistically help not only prevent and treat diabetes but also deal with any other complications associated with it. Currently, this invention is both locally and internationally patented. This patent protection can be said to be broad, and it bars existing technologies or pharmaceutical companies from using the stated formula and essentially the composition of 1-deoxynojirimycin and fagomine in the manufacture or improvement of existing blood glucose reduction remedies.

This invention can take the form of a pharmaceutical company, product line or just a product in the form of capsules, tablets, granules, dripping pills, powder, and oral liquid. Artificial red blood cells (Patent Number 7348399) This invention patent application number 11/433,259 was applied for in the U.S by Haynie Donald T. in May 2006 and is yet to be issued. It has been classified under current U.S class 530/300; 530/385 and current international class A61K 38/03 (20060101); A61K 38/16 (20060101).

Invention Summary It provides a new method for the identification of sequence motifs of a given net charge and length at a neutral pH in sequence information of amino acid for use in recording a required number of motifs and in ELBL. This is a seven step method consisting of (a) obtaining a peptide amino acid sequence from a given organism; (b) locating a starter amino acid; (c) examining the starter amino acid t determine the number of charged amino acids which have an opposite polarity; (d)